CAS No.: 2145096-91-
Molecular Weight: 143.02 kDa | Isotype: Human IgG4 kappa
Dosage Form: Injection (150mg/1ml) | Manufacturer: Shanghai Junshi Biosciences
Product Overview
Ongericimab (Synonyms: JS002) is a humanized anti-PCSK9 monoclonal antibody, a China-developed innovative drug, mainly used for lipid-lowering therapy with high efficacy and favorable safety profile.
Mechanism of Action
• Specifically binds to PCSK9, preventing its interaction with LDL receptors, thereby increasing LDL-C clearance and reducing blood lipid levels.
• Effectively lowers LDL-C and Lp(a) levels, reducing the risk of atherosclerotic cardiovascular disease (ASCVD).
Indications
Approved (NMPA, China): Primary hypercholesterolemia, mixed dyslipidemia, heterozygous familial hypercholesterolemia (HeFH), and statin-intolerant patients.
China [CN] 
Click enlarge Image